IPSEN, OOO
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
Efficacy and Safety Study of Dysport® Used for Migraine Prophylaxis
- Conditions
- Migraine
- First Posted Date
- 2006-03-13
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 138
- Registration Number
- NCT00301665
- Locations
- 🇸🇰
Faculty Hospital, Martin, Slovakia
🇵🇱Voivodeship (Provincial) Specialist Hospital, Zgierz, Poland
🇨🇿St. Anne's Faculty Hospital, Brno, Czechia
Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment
- Conditions
- Thyroid-Associated Ophthalmopathy
- First Posted Date
- 2006-02-08
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 5
- Registration Number
- NCT00288522
- Locations
- 🇪🇸
Hospital General d'Alacant, Alicante, Spain
Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
- Conditions
- Cervical Dystonia
- Interventions
- Biological: Botulinum toxin type A
- First Posted Date
- 2006-02-08
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 108
- Registration Number
- NCT00288509
- Locations
- 🇺🇸
University of Iowa, Dept of Neurology, Iowa City, Iowa, United States
🇺🇸Emory University School of Medicine, Wesley Woods Health Center, Atlanta, Georgia, United States
🇺🇸Albany Medical Center, Albany, New York, United States
A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints
- Conditions
- Memory Disorders, Age-RelatedRetention Disorders, Cognitive
- Interventions
- Drug: EGb 761® (Tanakan®)Other: Placebo
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 2878
- Registration Number
- NCT00276510
- Locations
- 🇫🇷
1 rue de l'Orient, Agde, France
🇫🇷3 Avenue de Marlioz, Aix les Bains, France
🇫🇷3 rue Auguste Delaune, Ales, France
Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 47
- Registration Number
- NCT00276341
- Locations
- 🇫🇷
CHU de Bordeaux, Bordeaux, France
🇫🇷Hopital Nord, Cebazat, France
🇫🇷CHG Dijon, Dijon, France
Study to Evaluate Smecta® vs Placebo on the Time to Recovery Following an Acute Diarrhoea Episode in Adults
- Conditions
- Diarrhea
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 346
- Registration Number
- NCT00276328
- Locations
- 🇹🇳
Cité Laouina, Sousse, Tunisia
🇹🇳rue Sidi Sahloul - Hammam, Sousse, Tunisia
🇹🇳Hôpital des F.S.I., La Marsa, Tunisia
Study of Long-term Use of Forlax® in Elderly Patients With Chronic Constipation
- Conditions
- Constipation
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 246
- Registration Number
- NCT00276354
- Locations
- 🇫🇷
19 rue Jules Guesde, Abscon, France
🇫🇷89 avenue de Niort, Beauvoir Sur Niort, France
🇫🇷39, avenue de France, Blois, France
Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial Spasm
- Conditions
- Hemifacial Spasm
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 332
- Registration Number
- NCT00276315
- Locations
- 🇨🇳
Neurology Department, Guangdong Provincial People's Hospital, Guangdong, China
🇨🇳Neurology Department, Peking Union Medical College Hospital, Beijing, China
🇨🇳Neurology Department, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China
A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke
- Conditions
- Stroke, AcuteNeurological Impairment
- Interventions
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 204
- Registration Number
- NCT00276380
- Locations
- 🇨🇿
General Faculty Hospital, Prague 2, Czechia
🇨🇿Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czechia
🇷🇴Institul de Boli Cerebro Vascular, Bucharest, Romania
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
- Conditions
- Cervical Dystonia
- Interventions
- Biological: Botulinum toxin type ADrug: Placebo
- First Posted Date
- 2005-11-23
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 116
- Registration Number
- NCT00257660
- Locations
- 🇺🇸
Parkinson's and Movement Disorder Institute, Fountain Valley, California, United States
🇺🇸USC School of Medicine, Los Angeles, California, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States